S0338, Imatinib Mesylate and Capecitabine in Treating Women With Progressive Stage IV Breast Cancer
Status:
Completed
Trial end date:
2008-12-01
Target enrollment:
Participant gender:
Summary
RATIONALE: Imatinib mesylate may stop the growth of tumor cells by blocking the enzymes
necessary for their growth. Drugs used in chemotherapy, such as capecitabine, work in
different ways to stop tumor cells from dividing so they stop growing or die. Combining
imatinib mesylate with capecitabine may kill more tumor cells.
PURPOSE: This phase II trial is studying how well giving imatinib mesylate together with
capecitabine works in treating women with progressive stage IV breast cancer.